"Clinically Validated AKK PROBIOTM: Redefining Gut Microbiome Balance"
"World's First Dual GRAS-Certified AKK Strain • China's Breakthrough in Microecology"
SHARE THE LOVE NOWAKK PROBIOTM Product Series

Introduction
Akkermansia muciniphila (AKK bacteria), a resident gut microbe, colonizes the intestinal mucosal layer. It interacts with immune cells via short-chain fatty acids to exert health-protective effects.
In 2019, we selected AKK PROBIO from 200 AKK strains. Its preservation number is CGMCC No.20955 (certified by the China General Microbiological Culture Collection Center).
Over 3,000 global studies confirm AKK bacteria's significant potential in intestinal barrier protection, weight management, anti-aging, and anti-inflammation, with broad application prospects.
Mechanism of Action
AKK bacteria regulate intestinal barrier function by activating receptors like FFAR2/3 via outer membrane protein Amuc_1100 and short-chain fatty acids (acetate, propionate), promoting goblet cell differentiation and mucus secretion. They also enhance glucose-lipid metabolism and insulin sensitivity by stimulating GLP-1/2 secretion, while inhibiting pro-inflammatory factors (IL-1β, IL-6) to boost immune regulation.


Key Advantages
Superior Stress Resistance: Maintains activity in pH 5.8-7.2 and low-oxygen environments; over 80% survival rate after 6 hours in gastrointestinal fluids, solving the colonization challenge of traditional probiotics.
Evolved Functionality: 2.81Mb genome with 2309 coding genes, including novel FIAF activation clusters and amuX gene, enhancing mucin degradation by 40% for better colonization.
Safety Benchmark: World's first AKK strain with dual FDA GRAS certifications (live and inactivated forms). Passed toxicology and drug resistance tests with no potential virulence factors.
About Us
Founded in 2016, Thankcome is a high-tech enterprise specializing in the entire probiotic industry chain (R&D, production, sales), and a subsidiary of Perfect Group (stock code: 603059). It holds 105 Chinese invention patents, 4 PCT patents, 4 Australian patents, 11 Hong Kong patents, and has published 63 academic papers (53 SCI) while leading 29 clinical studies.
With 2 R&D centers (Suzhou, Jiangsu; Suzhou, Anhui) and 1 production base (Suzhou, Anhui), planned capacity includes 200 tons/year of probiotic raw powder and 2,000 tons/year of preparations.
Frequently Asked Questions
Have a Question? We’ve Got the Answer!
Communicate with us via email
Register your email address to get our latest product news